BioCentury
ARTICLE | Clinical News

Lynparza meets in first-line ovarian cancer

June 27, 2018 9:55 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) said Lynparza olaparib as a first-line maintenance therapy improved progression-free survival (PFS) vs. placebo in patients with BRCA-mutated advanced ovarian cancer, meeting the primary endpoint of the Phase III SOLO-1 trial.

Lynparza is the first PARP inhibitor to significantly improve PFS in the first-line maintenance setting, according to the partners...